Newsletter | March 4, 2026

03.04.26 -- Breaking Through Tumor Defenses With Next-Generation Cell Therapy

FOCUS ON TRANSLATIONAL RESEARCH

Breaking Through Tumor Defenses With Next-Generation Cell Therapy

Ernexa Therapeutics CEO Sanjeev Luther shares how clinical research has revealed why certain cancers resist treatment and how emerging cell therapies may help break through those defenses.

Determining The Linear Range For Quantitative Western Blot Detection

Discover how to determine the linear range for western blot quantification using total protein stains or housekeeping proteins to ensure accurate normalization and avoid saturation effects.

Bridging Discovery And CMC With Rapid Pools

Learn how early stable CHO expression data reveals manufacturability issues in complex antibodies that transient screening misses, with case studies showing how this changes lead selection.

Powering More Efficient Clinical Development With AI And ML

Delve into how AI and ML are revolutionizing clinical trials by automating data processes to accelerate research and transform data into actionable outcomes for patient care.

Improving Clinical Translation Accuracy Through Organ-On-Chip Technology

Observe how Organ-on-Chip technology significantly enhances drug development processes and improves the accuracy of clinical translation, leading to more effective and reliable therapeutic outcomes.

TRANSLATIONAL RESEARCH SOLUTIONS

Bring The Power Of Electroporation To Accelerate Your Next Discovery - MaxCyte, Inc.

Immune Challenge Models For Early Drug Development - CHDR

Single Wash ELISA Kits, Unparalleled Simplicity And Effectiveness - Danaher Life Sciences

Connect With Cell & Gene: